PK Study of WD-1603 in Healthy Subjects

NCT ID: NCT04591535

Last Updated: 2020-10-19

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE1
• Total Enrollment: 8 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-09-28
• Study Completion Date: 2021-03-28

Brief Summary

An open label, balanced, randomised, four-treatment, four-period, four-sequence, single oral dose, crossover Pharmacokinetics study of WD-1603 carbidopa/levodopa extended-release tablets in normal, healthy, adult human subjects under fed conditions. A single oral dose of (either Treatment A or B or C or D) carbidopa/levodopa extended release tablets will be administered to each subject within 5 minutes after completion of standardized vegetarian breakfast under fed condition in each period as per randomization schedule.

Detailed Description

This is an open label, balanced, randomised, four-treatment, four-period, four-sequence, single oral dose, crossover Pharmacokinetics study of WD-1603 carbidopa/levodopa extended-release tablets in normal, healthy, adult human subjects under fed conditions. A single oral dose of (either Treatment A or B or C or D) carbidopa/levodopa extended release tablets will be administered to each subject within 5 minutes after completion of standardized vegetarian breakfast under fed condition in each period as per randomization schedule.

Conditions

Parkinson Disease

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

WD-1603 (tablet strength 4) single dose

A single oral dose of carbidopa/levodopa extended release tablets (WD-1603 tablet strength 4) will be administered to each subject within 5 minutes at 30 minutes after serving standardized vegetarian breakfast under fed condition in each period as per randomization schedule.

Group Type: EXPERIMENTAL

WD-1603 CARBIDOPA/LEVODOPA EXTENDED-RELEASE TABLETS

Intervention Type: DRUG

WD-1603 CARBIDOPA/LEVODOPA EXTENDED-RELEASE TABLETS

WD-1603 (tablet strength 1) single dose

A single oral dose of carbidopa/levodopa extended release tablets (WD-1603 tablet strength 1) will be administered to each subject within 5 minutes at 30 minutes after serving standardized vegetarian breakfast under fed condition in each period as per randomization schedule.

Group Type: EXPERIMENTAL

WD-1603 CARBIDOPA/LEVODOPA EXTENDED-RELEASE TABLETS

Intervention Type: DRUG

WD-1603 CARBIDOPA/LEVODOPA EXTENDED-RELEASE TABLETS

WD-1603 (tablet strength 2) single dose

A single oral dose of carbidopa/levodopa extended release tablets (WD-1603 tablet strength 2) will be administered to each subject within 5 minutes at 30 minutes after serving standardized vegetarian breakfast under fed condition in each period as per randomization schedule.

Group Type: EXPERIMENTAL

WD-1603 CARBIDOPA/LEVODOPA EXTENDED-RELEASE TABLETS

Intervention Type: DRUG

WD-1603 CARBIDOPA/LEVODOPA EXTENDED-RELEASE TABLETS

WD-1603 (tablet strength 3) single dose

A single oral dose of carbidopa/levodopa extended release tablets (WD-1603 tablet strength 3) will be administered to each subject within 5 minutes at 30 minutes after serving standardized vegetarian breakfast under fed condition in each period as per randomization schedule.

Group Type: EXPERIMENTAL

WD-1603 CARBIDOPA/LEVODOPA EXTENDED-RELEASE TABLETS

Intervention Type: DRUG

WD-1603 CARBIDOPA/LEVODOPA EXTENDED-RELEASE TABLETS

Interventions

WD-1603 CARBIDOPA/LEVODOPA EXTENDED-RELEASE TABLETS

WD-1603 CARBIDOPA/LEVODOPA EXTENDED-RELEASE TABLETS

Intervention Type: DRUG

Other Intervention Names

WD-1603

Eligibility Criteria

Inclusion Criteria

1. Normal, healthy adult human volunteers between 18 to 45 years of age (both inclusive).

2. Having a Body Mass Index (BMI) between 18.5 to 29.9 (both inclusive), calculated as weight in kg / height in m2, a minimum body weight of 50.0 kg.

3. Not having any significant disease or clinically significant abnormal findings during screening, medical history, clinical examination, laboratory evaluations, 12- lead ECG and X-ray chest (P/A view) recordings.

4. Able to understand and comply with the study procedures, in the opinion of the principal investigator.

5. Able to give voluntary written informed consent for participation in the trial.

6. In case of female subjects:

a. Surgically sterilized at least 6 months prior to study participation or If of child bearing potential is willing to use a suitable and effective double barrier contraceptive method or intra uterine device during the study.

And b. Serum Pregnancy test must be negative.

g.Female must also be willing to abstain from ovum donation from Screening and for at least 28 days after the last study drug administration.

h.Female subjects of non-childbearing potential must be either post-menopausal (post-menopausal is defined as being amenorrheic for at least 1 year without another cause and a follicle-stimulating hormone [FSH] level ≥26 IU/L) or surgically sterile (hysterectomy, bilateral oophorectomy, or bilateral tubal ligation).

i.Male subjects with female sexual partners of childbearing potential must be willing to use and willing to continue using medically acceptable contraception (true abstinence, vasectomy, or male condom for subjects plus an additional method of contraception for their female partners) from dosing until 28 days following the last administration of study drug.

j.Men must also be willing to abstain from sperm donation from Screening and for at least 28 days after the last study drug administration.

k.Subjects should be literate.

Exclusion Criteria

1. Known hypersensitivity or idiosyncratic reaction to Carbidopa or Levodopa or any of the excipients or any related drug.

2. History or presence of any disease or condition which might compromise the haemopoietic, renal, hepatic, endocrine, pulmonary, cardiovascular, immunological, dermatological, gastrointestinal system, and central nervous system with dyskinesia, depression, suicidal thought, or any other body system.

3. History or presence of ophthalmic diseases such as wide angle glaucoma and ocular hypertension.

4. Ingestion of a medicine (prescribed & over the counter (OTC) medication including herbal remedies and MAO inhibitors) at any time within 30 days before dosing in Period I. In any such case subject selection will be at the discretion of the Principal Investigator.

5. Any history or presence of asthma (including aspirin induced asthma) or nasal polyp or NSAIDs induced urticaria.

6. Use of any recreational drugs or history of drug addiction or testing positive in pre-study drug scans.

g.A recent history of harmful use of alcohol (less than 2 years), i.e. alcohol consumption of more than 14 standard drinks per week for men and more than 7 standard drinks per week for women (A standard drink is defined as 360 ml of beer or 150 ml of wine or 45 ml of 40% distilled spirits, such as rum, whisky, brandy etc) or consumption of alcohol or alcoholic products within 48 hours prior to dosing in Period I.

h.Smokers, who smoke 10 or more than 10 cigarettes / day or inability to abstain from smoking during the study.

i.The presence of clinically significant abnormal laboratory values during screening.

j.History or presence of psychiatric disorders. k.A history of difficulty in donating blood. l.Donation of blood (1 unit or 350 mL) within a period of 90 days prior to the first dose of study medication.

m.Receipt of an investigational medicinal product or participation in a drug research study within a period of 90 days prior to the first dose of study medication**.

• If investigational medicinal product is received within 90 days where there is no blood loss except safety lab testing, subject can be included considering 10 half-lives duration of investigational medicinal product received.

n.A positive hepatitis screen including hepatitis B surface antigen and/or HCV antibodies.

o.A positive test result for HIV (1 &/or 2) antibody. p.An unusual diet, for whatever reason (e.g. low-sodium), for four weeks prior to receiving the study medicine in period I. In any such case subject selection will be at the discretion of the Principal Investigator.

q.Consumption of grapefruit or grapefruit products within 72 hours prior to dosing in period-I.

r.Difficulty in swallowing oral solid dosage form like tablets or capsules. s.Nursing mothers (females).

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 45 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Hong Kong WD Pharmaceutical Co., Limited

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Shrikrishna Kolte, Doctor

Role: PRINCIPAL_INVESTIGATOR

Lambda Therapeutic Research Limited, Ahmedabad,India

Locations

Lambda Therapeutic Research Ltd.

Ahmedabad, , India

Site Status: RECRUITING

Countries

India

Central Contacts

Xiaoxiong Wei, Doctor

Role: CONTACT

xiaoxiong.wei@wdpharma.com

+86-21-6859-9718

Facility Contacts

Alpesh J Parmar, Doctor

Role: primary

alpeshjparmar@lambda-cro.com

+ 91-79-40202020

Other Identifiers

WD-1603-1003

Identifier Type: -

Identifier Source: org_study_id